Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Cabotegravir and Rilpivirine LA IM in Healthy Adults
NCT04371380Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cabotegravir and rilpivirine in human immunodeficiency virus infection (HIV), sponsored by ViiV Healthcare. Primary endpoints: Maximum Observed Concentration of Cabotegravir at Week 52, Maximum Observed Concentration of Rilpivirine at Week 52 and 10 more. Started Sep 2020; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04371380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04371380.